Literature DB >> 10547592

Angiogenic factor VEGF is decreased in human colorectal neoplasms showing DNA microsatellite instability.

C V Wynter1, L A Simms, R L Buttenshaw, K G Biden, J Young, B A Leggett, R J Conrad, E M Schoch, J R Jass, S Praga Pillay.   

Abstract

Vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) are two important determinants of angiogenesis in human cancers. Expression of VEGF and bFGF was examined by immunohistochemistry in 120 colorectal cancers. Neoplasms were classified according to the presence or absence of microsatellite instability determined at six microsatellite loci and labelled as a high microsatellite instability (MSI-H), low microsatellite instability (MSI-L) or microsatellite stable (MSS). Only 4/30 MSI-H cancers expressed VEGF (13 per cent), compared with 24/64 MSS cancers (38 per cent; p< 0.01). Fewer MSI-H cancers showed bFGF expression (38 per cent) than MSS cancers (53 per cent; p< 0.09). MSI-L cancers showed the same pattern as MSS cancers. Western blotting and immunohistochemistry showed that the tumour suppressor gene p53 was mutated infrequently in MSI-H cancers (8 per cent; p< 0. 001). Microvessel density counts using CD31 and UEA-1 demonstrated no difference in the number of blood vessels in MSI-H and MSS cancers. Although these results are consistent with the known role of wild-type p53 in down-regulating VEGF, no association was found between a mutation in p53 and VEGF or bFGF levels in all colonic neoplasms. This is the first evidence that MSI-H cancers may follow a different pathway to angiogenesis. The low frequency of VEGF expression amongst MSI-H cancers may partially explain why these cancers are less aggressive, with a better overall prognosis. Copyright 1999 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10547592     DOI: 10.1002/(SICI)1096-9896(199911)189:3<319::AID-PATH436>3.0.CO;2-2

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  7 in total

1.  Left and right sided large bowel cancer.

Authors:  Susan Richman; Julian Adlard
Journal:  BMJ       Date:  2002-04-20

2.  Differences of vascular endothelial growth factor (VEGF) expression between liver and abdominal metastases from colon cancer. Implications for the treatment with VEGF inhibitors.

Authors:  S Cascinu; F Graziano; V Catalano; M P Staccioli; S Barni; P Giordani; M C Rossi; A M Baldelli; P Muretto; A Valenti; G Catalano
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

3.  The value of single-source dual-energy CT imaging for discriminating microsatellite instability from microsatellite stability human colorectal cancer.

Authors:  Jingjun Wu; Yue Lv; Nan Wang; Ying Zhao; Pengxin Zhang; Yijun Liu; Anliang Chen; Jianying Li; Xin Li; Yan Guo; Tingfan Wu; Ailian Liu
Journal:  Eur Radiol       Date:  2019-03-22       Impact factor: 5.315

4.  The immunogenicity of colorectal cancers with high-degree microsatellite instability.

Authors:  Ayan Banerjea; Stephen A Bustin; Sina Dorudi
Journal:  World J Surg Oncol       Date:  2005-05-12       Impact factor: 2.754

5.  In silico evidence of signaling pathways of notch mediated networks in leukemia.

Authors:  Kaiser Jamil; Archana Jayaraman; Raghunatha Rao; Suryanarayana Raju
Journal:  Comput Struct Biotechnol J       Date:  2012-11-19       Impact factor: 7.271

6.  Prognostic impact of mismatch repair genes germline defects in colorectal cancer patients: are all mutations equal?

Authors:  Elena Maccaroni; Raffaella Bracci; Riccardo Giampieri; Francesca Bianchi; Laura Belvederesi; Cristiana Brugiati; Silvia Pagliaretta; Michela Del Prete; Mario Scartozzi; Stefano Cascinu
Journal:  Oncotarget       Date:  2015-11-17

Review 7.  Mismatch repair deficient colorectal cancer in the era of personalized treatment.

Authors:  Madeleine Hewish; Christopher J Lord; Sarah A Martin; David Cunningham; Alan Ashworth
Journal:  Nat Rev Clin Oncol       Date:  2010-02-23       Impact factor: 66.675

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.